Publications

Can antimicrobial susceptibility testing results for ciprofloxacin or levofloxacin predict susceptibility to a newer fluoroquinolone, gatifloxacin? Report from The SENTRY Antimicrobial Surveillance Program (1997-99). by Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39: 237-243

Multi-laboratory assessment of the linezolid spectrum of activity using the Kirby-Bauer disk diffusion method: Report of the Zyvox Antimicrobial Potency Study (ZAPS) in the United States. by Jones RN, Ballow CH and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 59-66

Validation of cefditoren MIC quality control ranges by a multi-laboratory study (2001). by Jones RN and Biedenbach DJ published in Diagn. Microbiol. Infect. Dis. 2001; 40 (1-2): 71-73

In vitro evaluation of BI 397, a novel glycopeptide antimicrobial agent. by Jones RN, Biedenbach DJ, Johnson DM and Pfaller MA published in J. Chemother. 2001; 13 (3): 244-254

Method preferences and test accuracy of antimicrobial susceptibility testing: Updates from the College of American Pathologists Microbiology Surveys Program. by Jones RN published in Arch. Pathol. Lab. Med. 2001; 125: 1285-1289

Recent trends in resistance to broad-spectrum antimicrobials in the United States (USA): Results from the MYSTIC/USA Programme, 1999-2000, Abstr. P27.105. by Jones RN, Biedenbach DJ, Stilwell MG, Pfaller MA, and The MYSTIC Participant Group published in Int. J. Antimicrob. Agents 2001; 17 (Suppl 1): S147-S148

In vitro evaluation of ertapenem (MK-0826), a long-acting carbapenem, tested against selected resistant strains. by Jones RN published in J. Chemother. 2001; 13 (4): 363-376

Prediction of enterococcal imipenem susceptibility using ampicillin or penicillin MICs: More evidence for a class concept. by Jones RN published in J. Clin. Microbiol. 2001; 39 (10): 3810-3811

Cefditoren in vitro activity and spectrum: A review of international studies using reference methods. by Jones RN, Pfaller MA, Jacobs MR, Appelbaum PC and Fuchs PC published in Diagn. Microbiol. Infect. Dis. 2001; 41 (1-2): 1-14

Spectrum and activity of three contemporary fluoroquinolones tested against Pseudomonas aeruginosa isolates from urinary tract infections in the SENTRY Antimicrobial Surveillance Program (Europe and the Americas; 2000): More alike than different! by Jones RN, Beach ML and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 41 (3): 161-163

MYSTIC (Meropenem Yearly Susceptibility Test Information Collection) closing summary. Hamburg, Germany, 10 May 2001. by Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 197-198

Determining the value of antimicrobial surveillance programs. by Jones RN and Masterton R published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 171-175

Worldwide prevalence of antimicrobial resistance in Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis in the SENTRY Antimicrobial Surveillance Program, 1997-1999. by Hoban DJ, Doern GV, Fluit AC, Roussel-Delvallez M and Jones RN. published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S81-S93

Surveillance of antibiotic resistance in European ICUs. by Hanberger H, Diekema D, Fluit A, Jones R, Struelens M, Spencer R and Wolff M published in J. Hosp. Infect. 2001; 48 (3): 161-176

BMS284756 potency and spectrum tested against over 10,000 bacterial bloodstream infection isolates from the SENTRY Antimicrobial Surveillance Program (2000). Abstr P40. by Gordon KA, Pfaller MA, Jones RN, Sader HS, Biedenbach DJ, Beach ML and the SENTRY Participants Group. published in J. Antimicrob. Chemother. 2001; 47 (Suppl 1): S26-S27

Antimicrobial susceptibility testing of clinical isolates of Bordetella pertussis from northern California: Report from the SENTRY Antimicrobial Surveillance Program. by Gordon KA, Fusco J, Biedenbach DJ, Pfaller MA and Jones RN. published in Antimicrob. Agents Chemother. 2001; 45 (12): 3599-3600

Contemporary assessment of antimicrobial susceptibility testing methods for polymyxin B and colistin: Review of available interpretative criteria and quality control guidelines. by Gales AC, Reis AO and Jones RN published in J. Clin. Microbiol. 2001; 39 (1): 183-190

Carbapenem-resistant Serratia marcescens isolates producing Bush group 2f β-lactamase (SME-1) in the United States: Results from the MYSTIC Programme. by Gales AC, Biedenbach DJ, Winokur P, Hacek DM, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 125-127

Activities of BMS 284756 (T-3811) against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus pneumoniae isolates from SENTRY Antimicrobial Surveillance Program medical centers in Latin America (1999). by Gales A, Sader HS and Jones RN published in Antimicrob. Agents Chemother. 2001; 45 (5): 1463-1466

Emerging importance of multidrug-resistant Acinetobacter species and Stenotrophomonas maltophilia as pathogens in seriously ill patients: Geographic patterns, epidemiological features, and trends in the SENTRY Antimicrobial Surveillance Program (1997-1999). by Gales AC, Jones RN, Forward KR, Linares J, Sader HS and Verhoef J published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S104-S113

Characterization of Pseudomonas aeruginosa isolates: Occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. by Gales AC, Jones RN, Turnidge J, Rennie R and Ramphal R published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S146-S155

Comparative antimicrobial spectrum and activity of BMS284756 (T-3811, a desfluoroquinolone) tested against 656 Enterobacteriaceae, including preliminary in vitro susceptibility test comparisons and development. by Fix AM, Pfaller MA, Biedenbach DJ, Beach ML and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (2): 141-145

Three independent yearly analyses of the spectrum and potency of metronidazole: A multicenter study of 1,108 contemporary anaerobic clinical isolates. by Erwin ME, Fix AM and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (2): 129-132

Antimicrobial resistance in viridans group streptococci among patients with and without the diagnosis of cancer in the USA, Canada and Latin America. by Diekema DJ, Beach ML, Pfaller MA and Jones RN published in Clin. Microbiol. Infect. 2001; 7 (3): 152-157

Survey of infections due to Staphylococcus species: Frequency of occurrence and antimicrobial susceptibility of isolates collected in the United States, Canada, Latin America, Europe, and the Western Pacific Region for the SENTRY Antimicrobial Surveillance Program, 1997- 1999. by Diekema DJ, Pfaller MA, Schmitz FJ, Smayevsky J, Bell J, Jones RN and Beach M published in Clin. Infect. Dis. 2001; 32 (Suppl 2): S114-S132

Oxazolidinone antibiotics. by Diekema DJ and Jones RN published in Lancet 2001; 358 (9297): 1975-1982

Accuracy of broth microdilution and Etest methods for detecting chloramphenicol acetyl transferase mediated resistance in Streptococcus pneumoniae: Geographic variations in the prevalence of resistance in The SENTRY Antimicrobial Surveillance Program (1999). by Deshpande LM, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 267-269

GAR-936 (9-t-butylglycylamido-minocycline) susceptibility test development for streptococci, Haemophilus influenzae and Neisseria gonorrhoeae: Preliminary guidelines and interpretive criteria. by Deshpande LM, Gales AC and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (1): 29-35

Antimicrobial activity of BMS 284756 (T-3811) against Neisseria gonorrhoeae tested by three methods. by Deshpande L, Biedenbach DJ and Jones RN published in Int. J. Antimicrob. Agents 2001; 18 (5): 437-440

Comparison of two commercial systems (Vitek and MicroScan-WalkAway) for antimicrobial susceptibility testing of Pseudomonas aeruginosa isolates from cystic fibrosis patients. by Burns JL, Saiman L, Whittier S, Krzewinski J, Liu Z, Larone D, Marshall SA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 257-260

In vitro activity of linezolid (U-100766) against Haemophilus influenzae measured by three different susceptibility testing methods. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 39 (1): 49-53

Activity of BMS284756 against 2,681 recent clinical isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the United States. by Biedenbach DJ, Jones RN and Pfaller MA published in Diagn. Microbiol. Infect. Dis. 2001; 39 (4): 245-250

In vitro antimicrobial activity of GAR-936 tested against antibiotic-resistant Gram-positive blood stream infection isolates and strains producing extended-spectrum β-lactamases. by Biedenbach DJ, Beach ML and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 40 (4): 173-177

Assessment of BMS284756 MIC and 5-µg disk diffusion quality control studies tested against seven American type culture collection strains. by Biedenbach DJ and Jones RN published in Diagn. Microbiol. Infect. Dis. 2001; 41 (4): 225-228

In vitro activity of selected cephalosporins and erythromycin against staphylococci and pneumococci isolated at 38 North American medical centers participating in the SENTRY Antimicrobial Surveillance Program, 1997-1998. by Jones RN, Jenkins SG, Hoban DJ, Pfaller MA and Ramphal R published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 93-98

Respiratory tract pathogens isolated from patients hospitalized with suspected pneumonia: Frequency of occurrence and antimicrobial susceptibility patterns from the SENTRY Antimicrobial Surveillance Program (United States and Canada, 1997). by Jones RN, Croco MA, Kugler KC, Pfaller MA and Beach ML published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 115-125

Cefditoren activity against nearly 1,000 non-fastidious bacterial isolates and the development of in vitro susceptibility test methods. by Jones RN, Biedenbach DJ and Johnson DM published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 143-146

Development of gemifloxacin in vitro susceptibility test methods for gonococci including quality control guidelines. The Quality Control Study Group. by Jones RN and Erwin ME published in Diagn. Microbiol. Infect. Dis. 2000; 37 (3): 195-201

Evaluation of gemifloxacin (SB-265805, LB20304a): In vitro activity against over 6,000 Gram-positive pathogens from diverse geographic areas. by Jones RN, Pfaller MA and Erwin ME published in Int. J. Antimicrob. Agents 2000; 15 (3): 227-230

Perspectives on the development of new antimicrobial agents for resistant Gram-positive pathogens. by Jones RN published in Braz. J. Infect. Dis. 2000; 4 (1): 1-8

In vitro activity of newer fluoroquinolones for respiratory tract infections and emerging patterns of antimicrobial resistance: Data from the SENTRY Antimicrobial Surveillance Program. by Jones RN and Pfaller MA. published in Clin. Infect. Dis. 2000; 31 (Suppl 2): S16-23

Detection of emerging resistance patterns within longitudinal surveillance systems: Data sensitivity and microbial susceptibility. MYSTIC Advisory Board. Meropenem Yearly Susceptibility Test Information Collection. by Jones RN published in J. Antimicrob. Chemother. 2000; 46 (Suppl T2): 1-8

Macrolide and fluoroquinolone (levofloxacin) resistances among Streptococcus pneumoniae strains: Significant trends from the SENTRY Antimicrobial Surveillance Program (North America, 1997-1999). by Jones RN and Pfaller MA published in J. Clin. Microbiol. 2000; 38 (11): 4298-4299

Potencies of newer fluoroquinolones against viridans group streptococci isolated in 637 cases of bloodstream infection in the SENTRY Antimicrobial Surveillance Program (1997 to 1999): Beyond Canada! by Jones RN and Pfaller MA published in Antimicrob. Agents Chemother. 2000; 44 (10): 2922-2923

Antimicrobial activity and in vitro susceptibility test development for cefditoren against Haemophilus influenzae, Moraxella catarrhalis, and Streptococcus species. by Johnson DM, Biedenbach DJ, Beach ML, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 37 (2): 99-105

Activity and spectrum of 22 antimicrobial agents tested against urinary tract infection pathogens in hospitalized patients in Latin America: Report from the second year of the SENTRY Antimicrobial Surveillance Program (1998). by Gales AC, Jones RN, Gordon KA, Sader HS, Wilke WW, Beach ML, Pfaller MA and Doern GV published in J. Antimicrob. Chemother. 2000; 45 (3): 295-303

Two-year assessment of the pathogen frequency and antimicrobial resistance patterns among organisms isolated from skin and soft tissue infections in Latin American hospitals: Results from the SENTRY Antimicrobial Surveillance Program, 1997-98. SENTRY Study Group. by Gales AC, Jones RN, Pfaller MA, Gordon KA and Sader HS published in Int. J. Infect. Dis. 2000; 4 (2): 75-84

Antimicrobial activity and spectrum of the new glycylcycline, GAR-936 tested against 1,203 recent clinical bacterial isolates. by Gales AC and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 19-36

Occurrence of single-point gyrA mutations among ciprofloxacin-susceptible Escherichia coli isolates causing urinary tract infections in Latin America. by Gales AC, Gordon KA, Wilke WW, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2000; 36 (1): 61-64

Oxazolidinones: A review. by Diekema DI and Jones RN published in Drugs 2000; 59 (1): 7-16